Milton Daugherty
Psychiatry · Chicago, ILNPI 1124100896
Payments from drug & device makers
Across 179 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Neurocrine Biosciences, Inc.$673
- Teva Pharmaceuticals USA, Inc.$592
- Johnson & Johnson$328
- Vanda Pharmaceuticals Inc.$327
- Otsuka America Pharmaceutical, Inc.$212
- plus $281 from 5 others
What the payments were for
- Food & beverage$3,58698%
- Education$862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 69 | $1,258 |
| Neurocrine Biosciences, Inc. | 34 | $673 |
| Teva Pharmaceuticals USA, Inc. | 22 | $592 |
| Johnson & Johnson | 13 | $328 |
| Vanda Pharmaceuticals Inc. | 12 | $327 |
| Otsuka America Pharmaceutical, Inc. | 11 | $212 |
| Alkermes, Inc. | 8 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $84 |
| Indivior Inc. | 3 | $39 |
| Lundbeck LLC | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$125
How this compares
$3,672 in reported general payments places this provider in the 85th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 34 | $81,130 |
| Divalproex Sodium ErDivalproex Sodium | 25 | $1,230 |
| Divalproex Sodium | 19 | $1,023 |
| Risperidone | 58 | $672 |
| Quetiapine Fumarate | 44 | $556 |
| Olanzapine | 13 | $513 |
| Benztropine Mesylate | 34 | $487 |
| Trazodone Hcl | 17 | $169 |
| Mirtazapine | 11 | $160 |
| Clonazepam | 14 | $98 |
| Buspirone Hcl | 11 | $89 |
| Escitalopram Oxalate | 12 | $70 |
| Lorazepam | 20 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $328 | $81,13034 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Chicago
- Yuhwen ChowChicago$8.5M
- Jon GrantChicago$1.4M
- Jeffrey RadoChicago$1.2M
- Mitchell GlaserChicago$1.1M
- Peter WeidenChicago$941K
- Brett PlylerChicago$293K
- Michelle DeesChicago$289K
- Jennifer SpragueChicago$288K
- K Ranga KrishnanChicago$92K
- Pawel DudekChicago$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.